Matinas BioPharma Announces Stock Sale for Shareholders

Matinas BioPharma has filed to sell 16.9 million shares of common stock for holders. The move is aimed at raising capital to support the company's operations and growth. The filing does not specify the exact amount of money the company plans to raise. As a finance expert, I would note that the sale of common stock is a common practice for biotech companies looking to raise capital and fund their research and development efforts.

Matinas BioPharma Holdings, Inc. has filed with the Securities and Exchange Commission (SEC) to sell up to 16,894,212 shares of common stock. The move is aimed at raising capital to support the company's operations and growth, as disclosed in a Form S-3 registration statement filed on April 22, 2025 [1]. The exact amount of money the company plans to raise is not specified in the filing.

The sale of common stock is a common practice for biotech companies looking to raise capital and fund their research and development efforts. This latest filing by Matinas BioPharma is a strategic move to secure additional funding, which could potentially accelerate the company's growth and innovation in the biopharmaceutical sector.

The shares of common stock are being offered by the Selling Stockholders, who include holders of Series C Convertible Preferred Stock and warrants issued in a private placement offering. The private placement closed in two separate closings on February 13, 2025, and April 8, 2025 [1].

Investors should be aware that the sale of these securities involves a high degree of risk, as outlined in the company's annual report and other filings with the SEC [1]. The SEC has not approved or disapproved of these securities, and the preliminary prospectus is subject to completion and may be changed [1].

Matinas BioPharma's common stock is listed on the NYSE American under the symbol "MTNB." The last reported sale price of the common stock as of April 21, 2025, was $0.5570 [1].

References:
[1] https://quantisnow.com/insight/sec-form-s3-filed-by-matinas-biopharma-holdings-inc-5996867